REFERENCES

1. Basly JP (2005) Dietary phytoestrogens: potential selective estrogen enzyme modulator. Planta Med , 71; 287-294
2. Brand WW (1995), Use of a free radical method to evaluate antioxidant activity, Food Sci. Technol, 82; 25-30.
3. Cheung j (2003), Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestrodiol and raloxifene. J Endocrinol,177; 423-33.
4. Davison S(2003), Hormone replacement therapy: current controversies,Clin Endocrinol, 58;249–61.
5. Delmas P (1995),Biochemical markers of bone turnover Acra Orthop Scand , 66; 176-1 82.
6. Fraser JHE (1996), Hydrogen peroxide, but not superoxide, stimulates bone resorption in mouse calvariae. Bone 19(3);223-226.
7. Frost HM (1992), On the rat model of human osteopenias and osteoporoses, Bone Miner, 18; 227-236.
8. Gautam A (2010), Identification, evaluation and standardization of herbal drugs: A review , Der Pharmacia Lettre, 2; 302-315
9. Gollapalle L (2011), Antiosteoporotic activity of methanoloic extract od an indian herbal formula in ovarictomized rat, J. Chinese Integr.med.10;1125-1132.
10. Goodman (2006),Pharmacological basis of therapeutics,Mcgraw-hill,11;1662-72.
11. Harada SI (2003), Control of osteoblast function and regulation of bone mass. Nature, 423; 349–55.
12. Ho j (2008), Dioscorea improves the morphometric and mechanical properties of bone in ovariectomised rats, J Sci Food Agric 88; 2700–2706.
13. Kanis JA (2008), A reference standard for the discription of osteoporosis, Bone, 42; 467-475.
14. Kimmel DB(1996). Animal models for in vivo experimentation in osteoporosis research. In Osteoporosis; 671-690.

15. Kupferer EM (2009), Complementary and alternative medicine use for vasomotor symptoms among women who have discontinued hormone therapy, J. Obstet. Gynecol. Neonatal Nurs. 38; 50-59.
16. Lean JM (2005), Hydrogen peroxide is essential for estrogen-deficiency bone loss and osteoclast formation. Endocrinol, 146(2);728-735.
17. Moorehead WR(1974), Briggs HC. Clinical Chem; 20: 1458.
18. Mundy Gr (1996), osteoporosis into the yeay 2010. Br j Obstet Gyanaecol.103;32-37.
19. Nelson HD(2002), Postmenopausal hormone replacement therapy: scientific review. JAMA , 288;872–81.
20. OECD (2001), OECD Guideline 425: Acute Oral Toxicity-Up-and-Down Procedure. In: OECD Guidelines for the Testing of Chemicals Vol.2 Organization for Economic Cooperation and Development. Paris, France.
21. Parhizkar S (2008), Incision choice in laparatomy:a comparison of two incision techniques in ovariectomy of rats, WorldApple Sci. J. 4; 537-540.
22. Peng Z(1999), Alteration in the mechanical competence and structural properties in the femoral neck and vertebrae of ovariectomised rats. J. Bone Miner. Res; 14: 616-623.
23. Riggs BL(1992), The prevention andtreatment of osteoporosis. N Engl J Med; 327: 620-627.
24. Reddy NP (2003), Prevention of bone loss in calcium deficient ovariectomized rats by OST-6, a herbal preparation, J Ethnopharmacol,84 ; 259-264.
25. Sahil k (2011), Standardization of medicinal plant materials,IJRAP, 2 ;1100-1109
26. Sánchez-Rodríguez MA (2007), Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes, BMC Musculoskelet. Disord. 8;124-130.
27. Sánchez-Rodríguez MA (2007), Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes,BMC Musculoskelet. Disord, 8;124-130.
28. Seiler D, Nagel(1983), Tritschler W, Losser S. J.Clin.Chem.Clin.Biochem; 21: 519.

29. Shirke SS (2008), Methanolic extract of Cuminum cyminum inhibits ovariectomy induced bone loss in rats. Exp. Biol. Med. 233;1403-1410.
30. Wilkinson JH(1969), Winsten S, Clin Chem; 15:487.